Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Colon Cancer
  •  Stomach Cancer
  •  Carcinomas
  •  Adjuvant Therapy
  •  Palliative Care
  •  Prostate Cancer
  •  Radiation Oncology
  •  Immunology

Abstract

Citation: Clin Oncol. 2020;5(1):1721.DOI: 10.25107/2474-1663.1721

A Genetic Predictive Model for Precision Treatment of Diffuse Large B-Cell Lymphoma with Early Progression

Jialin Ma, Zheng Yan, Jiuyang Zhang, Wenping Zhou, Zhihua Yao, Haiying Wang, Junfeng Chu, Shuna Yao, Shuang Zhao, Peipei Zhang, Yuanlin Xu, Qingxin Xia, Jie Ma, Bing Wei, Shujun Yang, Kangdong Liu, Yongjun Guo and Yanyan Liu

Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, China Department of Molecule and Pathology, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, China China-US (Henan) Hormel Cancer Institute, China # These authors contributed equally to this work

*Correspondance to: Yanyan Liu 

 PDF  Full Text Research Article | Open Access

Abstract:

Early progression after standard immunochemotherapy leads to a very dismal outcome and necessitates alternative treatment for patients with Diffuse Large B-Cell Lymphoma (DLBCL). This study aimed to develop a genetic predictive model for early progression and evaluate its potential in advancing alternative treatment. Thirty-two hotspot driver genes were examined in 145 DLBCL patients and 5DLBCL cell lines using next-generation sequencing. By analyzing the association of clinical features, cell-of-origin, double expression, positive p53 protein, and gene alterations with early progression, a powerful genetic predictive model incorporating lactate dehydrogenase levels, CD79B mutations, and PIM1 mutations was developed which was validated in the other cohort. The potential of novel treatment based on the modeling was investigated in in vitro DLBCL cell lines and in vivo xenograft mouse models. CD79B and PIM1 mutations were significantly associated with double expression and indicated a better response to inhibitors of BTK (ibrutinib) and pan-PIM kinase (AZD 1208) through repressing activated oncogenic signaling. Since the two inhibitors failed to decrease BCL2 level, BCL2 inhibitor (venetoclax) was added and demonstrated to enhance their apoptosis-inducing activity in mutant cells with double expression. The genetic predictive model provides a robust tool to identify early progression and determine alternative treatment.

Keywords:

Diffuse large B-cell lymphoma; Early progression; CD79B; PIM1

Cite the Article:

Ma J, Yan Z, Zhang J, Zhou W, Yao Z, Wang H, et al. A Genetic Predictive Model for Precision Treatment of Diffuse Large B-Cell Lymphoma with Early Progression. Clin Oncol. 2020; 5: 1721.

Search Our Journal

Journal Indexed In

Articles in PubMed

Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
NMR Metabolomics in Ionizing Radiation
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Achillea fragrantissima: Pharmacology Review
 Abstract  PDF  Full Text
Influence of Hydrocortisone in Chemotherapy and Photodynamic Therapy in HEp-2 Cells
 Abstract  PDF  Full Text
View More...